Evolution of a New Class of Antihypertensive Drugs

A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension

(2019) Michel Azizi et al.   JOURNAL OF HYPERTENSION

Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins

(2019) Keith C. Ferdinand et al.   CIRCULATION

NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension

(2019) Mathilde Keck et al.   HYPERTENSION

Emerging Drug Classes and Their Potential Use in Hypertension

(2019) Michel Azizi et al.   HYPERTENSION

Central antihypertensive effects of chronic treatment with RB150

(2018) Yannick Marc et al.   JOURNAL OF HYPERTENSION

The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7)

(2018) Robson Augusto Souza Santos et al.   PHYSIOLOGICAL REVIEWS

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

(2018) Robert M. Carey et al.   HYPERTENSION

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Mohammad H Forouzanfar et al.   LANCET

A new strategy for treating hypertension by blocking the activity of the brain renin–angiotensin system with aminopeptidase A inhibitors

(2014) Ji Gao et al.   CLINICAL SCIENCE

Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug

(2013) Fabrice Balavoine et al.   CLINICAL PHARMACOKINETICS

Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction

(2012) Bing S. Huang et al.   CARDIOVASCULAR RESEARCH

Central Antihypertensive Effects of Orally Active Aminopeptidase A Inhibitors in Spontaneously Hypertensive Rats

(2012) Yannick Marc et al.   HYPERTENSION

Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients

(2012) Alan H. Gradman et al.   HYPERTENSION

Therapy of Hypertension in African Americans

(2011) John M. Flack et al.   American Journal of Cardiovascular Drugs

Management of High Blood Pressure in Blacks

(2010) John M. Flack et al.   HYPERTENSION

Drug Therapy for Resistant Hypertension: Simplifying the Approach

(2010) Samuel J. Mann   Journal of Clinical Hypertension

The Hypertension Paradox — More Uncontrolled Disease despite Improved Therapy

(2009) Aram V. Chobanian   NEW ENGLAND JOURNAL OF MEDICINE

Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure

(2008) Laurence Bodineau et al.   HYPERTENSION

Global burden of obesity in 2005 and projections to 2030

(2008) T Kelly et al.   INTERNATIONAL JOURNAL OF OBESITY

Human brain aminopeptidase A: biochemical properties and distribution in brain nuclei

(2008) Nadia de Mota et al.   JOURNAL OF NEUROCHEMISTRY

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

(2008) Kenneth Jamerson et al.   NEW ENGLAND JOURNAL OF MEDICINE